5. Фармакокинетика инъекционной фор

5. Фармакокинетика инъекционной формы Мексидола у больных при однократном и длительном приемах. Клиническую фармакокинетику мексидола изучали на 12 больных с расстройствами психо-неврологического статуса, находившихся на лечении в стационаре. Препарат назначался внутримышечно (по 200-250 мг два раза в сутки); пробы крови отбирали из локтевой вены непосредственно перед введением препарата, а также через 0,25; 0,5; 1,0; 2,0 и 4,0 часа после введения. Наличие взаимосвязи между фармакокинетическими параметрами и основными эффектами Мексидола свидетельствует о возможности использования данных фармакокинетики для индиви¬дуализации и оптимизации терапии больных с погра¬ничными состояниями нервно-психического статуса.

Результаты (английский) 1:

5. Pharmacokinetics of injection forms in patients with single-Mexidola and long receptions. Clinical farmakokinetiku mexidola studied on 12 patients with psycho-neurological disorders treated in hospital. The drug was prescribed injection (200-250 mg twice a day); blood samples selected from the ulnar veins directly before the introduction of the drug, as well as through 0.25; 0.5; 1.0; 2.0 and 4.0 hours after injection. The relationship between the pharmacokinetics parameters and basic effects Mexidola demonstrates that it is possible to use the data to individual pharmacokinetics ¬ dualization and optimization of therapy patients with BOR ¬ ničnymi States of mental status.

Результаты (английский) 2:

5. The pharmacokinetics of injectable form Mexidol in patients with single and long-term methods. Clinical pharmacokinetics mexidol was studied in 12 patients with disorders of the psycho-neurological status, were treated in hospital. The drug is administered intramuscularly (200-250 mg twice daily); Blood samples were collected from the cubital vein immediately before administration and at 0.25; 0.5; 10; 2.0 and 4.0 hours after administration. The relationship between pharmacokinetic parameters and the basic effects Mexidol indicates the possibility of using the data for the pharmacokinetics indivi¬dualizatsii and optimize treatment of patients with pogra¬nichnymi states of mental status.

Результаты (английский) 3:

5. Pharmacokinetics blood transfusions Мексидола form in patients when pressed once and prolonged interrogation. Clinical фармакокинетику мексидола studied in 12 patients with disorders psycho-blood coagulability status,Those who received treatment in the hospital. The Medication was appointed intramuscular injection (200-250 mg twice a day); blood samples confiscated from the ulna Vienna directly before the introduction of the drug, as well as through 0.25 ; 0.5 ; 1.0; 2.0 and 4,0 hours after the introduction.The relationship between фармакокинетическими parameters and the main effects Мексидола showed that it was possible to use of the data for individual pharmacokinetics of oil weighted densities and optimize therapy patientsПогра¬ничными statuses nerve mental status.